OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer
“We’re proud to partner with BrainChild Bio, a company that exemplifies patient-centered innovation in pediatric oncology,” said Michael May, President and CEO of OmniaBio. “While many CAR-T developers have solely prioritized clinical outcomes, often leaving manufacturing and supply considerations for later, BrainChild is redefining that approach—placing much needed emphasis on reliability, affordability, and thus patient access by working with OmniaBio.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.